Status:
COMPLETED
Baclofen Treatment of Ataxia Telangiectasia
Lead Sponsor:
Johns Hopkins University
Conditions:
Ataxia Telangiectasia
Eligibility:
All Genders
12+ years
Phase:
EARLY_PHASE1
Brief Summary
This research is being done to find out if Baclofen, a medicine that is often used for the treatment of abnormal stiffness, might also be useful to treat some of the neurologic problems caused by atax...
Eligibility Criteria
Inclusion
- Teenagers over 12 years old and young adults with A-T may join if they have been evaluated previously in the A-T Clinical Center at Johns Hopkins Hospital and have a measurable abnormality of eye movement.
- Patients who are presently taking Baclofen will be eligible for the study if they are presently receiving the medication under the direction of Dr. Crawford in the ATCC, and are willing to withdraw from the medication for a period of one month prior to the initial screening visit.
- Female patients who are sexually active will be given a standard serum HCG pregnancy test.
- Those who are sexually active will be counseled about necessary precautions against pregnancy during the duration of the trial.
Exclusion
- A positive pregnancy test.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00640003
Start Date
April 1 2007
End Date
February 1 2011
Last Update
December 20 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21108
2
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287